Latest Commercialization News

Hiremii Limited reported a near-flat revenue for FY2025 with a 25% increase in net loss, while pushing forward its AI-driven recruitment platform and completing a key acquisition to expand market reach.

RemSense Technologies posted a 107% revenue surge to $3.44 million in FY2025 alongside a 67% reduction in net loss, driven by operational efficiencies and strong client demand. The company achieved positive cash EBITDA and strengthened its global footprint with Tier 1 clients.

WhiteHawk Limited reports an 8.6% revenue increase and a 26% reduction in net loss for H1 2025, alongside new US government contracts and a $1.56 million capital raise.

Noxopharm Limited reported a 36.5% increase in its annual loss to $4.88 million as it progressed preparations for its SOF-SKN™ clinical trial and secured $2.6 million through convertible notes. The biotech continues to invest heavily in its inflammation and oncology drug pipeline while managing liquidity and strategic partnerships.

Cettire Limited reported FY25 results showing stable sales revenue and a breakeven adjusted EBITDA despite a challenging luxury goods market. The company’s strategic focus on profitability, supply chain expansion, and emerging markets diversification underpins its resilience.

Cettire Limited reported stable revenue for FY25 despite a challenging luxury market, but profitability sharply declined due to increased promotional activity and softer demand.

Clean TeQ Water Limited reported a reduced loss of $2.8 million for FY25 and increased its stake in Go2Lithium Inc to 60%, marking a strategic shift as it advances water treatment and critical metals recovery projects worldwide.

BlinkLab Limited reported a substantial net loss of $5.7 million for FY2025, driven by intensive R&D and clinical trial activities, while securing $7.66 million in fresh capital to fuel its smartphone-based neurodevelopmental diagnostic platform targeting autism and ADHD.

Cynata Therapeutics reported a $9.39 million net loss for FY2025, slightly improved from the prior year, while progressing multiple clinical trials with key results expected in 2026. The company maintains a solid cash position and funding runway through mid-2026, supported by recent capital raises and an equity subscription agreement.

Sparc Technologies reported a narrower FY25 loss alongside progress in green hydrogen and graphene additive projects, supported by government grants and a successful capital raise.

Alexium International Group Limited posted a 42.2% increase in net loss for FY2025, with revenues down 33.4% due to a soft US mattress market. Despite financial setbacks, the company advanced key technologies and announced leadership changes that could fuel future growth.

NTAW Holdings Limited has delivered a strong second-half turnaround in FY2025, posting a $30.3 million Operating EBITDA despite a full-year net loss. Under new leadership, the company is setting the stage for consolidation and growth in FY2026.